sarcoma/hnačka

Odkaz sa uloží do schránky

Vyberte typ zoradenia

10 výsledky

Alectinib in Combination With Bevacizumab in ALK Positive NSCLC

Články môžu prekladať iba registrovaní používatelia

Prihlásiť Registrácia

BACKGROUND The burden of Lung Cancer Lung cancer remains the most lethal malignancy worldwide, claiming more lives compared to any other malignant disease in both developed and developing countries, as well as globally. Although some countries have accomplished a decrease in incidence rates, most

Effect of Nurse-led Education on Parent's Anxiety and Depression on Managing Side Effects of Chemotherapy

Články môžu prekladať iba registrovaní používatelia

Prihlásiť Registrácia

INTRODUCTION Background Children Cancer in Pakistan: Millions of people are affected by cancer worldwide. Cancer is one of the major health problems in Pakistan . About 8,000 children below 18 year were diagnosed with cancer annually. Most children diagnosed in advance stage . In Pakistan 31%

Study of the Pan-DAC Inhibitor AR-42 and Pazopanib in Advanced Sarcoma and Kidney Cancer

Články môžu prekladať iba registrovaní používatelia

Prihlásiť Registrácia

This study was a single-arm, open-label, dose escalation phase 1 trial to determine the RP2Ds of AR-42 and pazopanib when given in combination to patients with advanced Renal Cell Carcinoma (RCC) or Soft Tissue Sarcoma (STS). Eligible patients had recurrent, unresectable, or metastatic RCC or STS

Pazopanib Tolerability When Given With Food

Články môžu prekladať iba registrovaní používatelia

Prihlásiť Registrácia

Pazopanib (Votrient) is a multi targeted tyrosine kinase inhibitor of vascular endothelial growth factor receptor, (VEGFR-1, -2 en -3), platelet-derived growth factor receptor (PDGFR-α and -β), and stem cell factor receptor (c-KIT). Pazopanib is registered for the treatment of patients with advanced

Nelfinavir and Lenalidomide/Dexamethasone in Progressive Multiple Myeloma

Články môžu prekladať iba registrovaní používatelia

Prihlásiť Registrácia

Disease background: MM is a plasma cell tumor. It accounted for an estimated 20,180 new cases of cancer and 11,170 deaths in the United States in 2010. With a prevalence of 23 per 100,000 people, MM is an orphan disease (prevalence <5:10,000). The median age at diagnosis is 60-65 years. Although MM

Trial of Docetaxel and Irinotecan (DI) for Recurrent or Refractory Bone and Soft Tissue Sarcomas.

Články môžu prekladať iba registrovaní používatelia

Prihlásiť Registrácia

Treatment setting:Hospitalization is preferred, but treatment on the outpatient base is allowed. Regimen and premedication 1. Regimen Docetaxel 100 mg/m2 mixed in D5W or N/S IV over 60 min: Day 1 Irinotecan 80 mg/m2 mixed in D5W IV over 90 min: Days 1 and 8 2. Premedications Dexamethasone 3 mg/m2 PO

Effects of Maraviroc (MVC) on HIV-related Kaposi's Sarcoma (KS)

Články môžu prekladať iba registrovaní používatelia

Prihlásiť Registrácia

Although the advent of antiretroviral therapy (ART) may have greatly decreased the incidence of Kaposi's Sarcoma (KS) in resource rich settings, KS continues to be the most prevalent AIDS-defining malignancy in the world and carries with it significant morbidity and mortality[1]. Indeed, in a recent

HAI Irinotecan + IV Bevacizumab, Bevacizumab & Oxaliplatin or Bevacizumab & Cetuximab in Advanced Cancers Metastatic to Liver

Články môžu prekladať iba registrovaní používatelia

Prihlásiť Registrácia

The Study Drugs: Irinotecan is designed to stop cancer cells from making new DNA (the genetic material of cells). This may cause cancer cells to die. Bevacizumab is designed to prevent or slow down the growth of cancer cells by blocking the growth of blood vessels that supply nutrients necessary for

Open Label Trial of Perifosine in Patients Currently Being Treated on Perifosine Trials in Solid Tumors or Multiple Myeloma

Články môžu prekladať iba registrovaní používatelia

Prihlásiť Registrácia

Perifosine is an oral anticancer agent with limited toxicity and a novel mechanism of action that is distinctly different from cytotoxic chemotherapies. It has been shown to inhibit and otherwise modify signaling through a number of pathways including Akt, p21, and JNK. Perifosine has been tested in

Testosterone and Physical Function in HIV+ Men

Články môžu prekladať iba registrovaní používatelia

Prihlásiť Registrácia

Purpose. Although the prevalence of weight loss in HIV-infected individuals has decreased in the developed world with the availability of highly active antiretroviral therapy, it continues to be a significant problem worldwide, and in the USA. The pathophysiology of weight loss in HIV-infected

Pripojte sa k našej
facebookovej stránke

Herbal & Natural Medicine

Najkompletnejšia databáza liečivých bylín podporovaná vedou

Pracuje v 55 jazykoch
Bylinné lieky podporené vedou
Rozpoznávanie bylín podľa obrázka
Interaktívna GPS mapa - označte byliny na mieste (už čoskoro)
Prečítajte si vedecké publikácie týkajúce sa vášho hľadania
Vyhľadajte liečivé byliny podľa ich účinkov
Usporiadajte svoje záujmy a držte krok s novinkami, klinickými skúškami a patentmi

Zadajte príznak alebo chorobu a prečítajte si o bylinách, ktoré by vám mohli pomôcť, napíšte bylinu a pozrite sa na choroby a príznaky, proti ktorým sa používa.
* Všetky informácie sú založené na publikovanom vedeckom výskume